A substantial portion of biopharma investments is allocated to financing clinical development. Successful clinical trials are crucial for regulatory approval and asset success.

When working with investors, it is important to consider how your clinical development strategy and trials design aligns with investment priorities. Investors are interested in optimizing time, cost, and, most important, the probability of success of a funded clinical development program.

In this Cytel webinar, Dr Bruce Leuchter, President & CEO of Neurvati Neurosciences, Dr. Michael Panzara, CMO at Neurvati Neurosciences and Dr. Natalia Muehlemann, Vice President Strategic Consulting at Cytel, will discuss how integration of adaptive approaches and Bayesian methods help make your clinical program more attractive and facilitate your communication with investors.

Key Topics

• Quantification of uncertainties and risks affecting investment decisions
• Evaluating Probability of Success
• De-risking clinical development and investments though interim decision-making
• Balance trade-offs with adaptive design options

Speakers

Dr. Bruce Leuchter

President, CEO and board member of Neurvati Neurosciences and GRIN Therapeutics  

Dr. Leuchter is a neuropsychiatrist with extensive experience in clinical research and biotechnology investments. He has held leadership roles at Goldman Sachs, Credit Suisse, and PJT Partners.

Dr. Michael A. Panzara, MD, MPH

Chief Medical Officer, Neurvati Neurosciences and GRIN Therapeutics
Dr. Panzara has over 23 years’ experience leading neurology programs at Biogen, Genzyme, Sanofi, Wave Life Sciences.  He currently serves on the boards at Athira Pharma and Cadenza Bio.

Dr. Natalia Muehlemann, MD, MBA

Vice President, Strategic Consulting, Cytel

Natalia Muehlemann has over 20 years of experience in Life Sciences across several therapeutic areas and combines medical, statistics & data science and strategic expertise.